Targeting ROCK2 may offer a therapeutic approach for chronic graft-versus-host disease (#cGVHD). This phase Ib study finds encouraging responses and a manageable safety profile with TDI01, a highly selective ROCK2 inhibitor.

#STTT #OpenAccess: doi.org/10.1038/s413...
#Fibrosis #TCellImmunity